We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.


Download Mobile App
Recent News COVID-19 Clinical Chemistry Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry News

US National COVID-19 Diagnostic Supply Registry Launched to Provide Updates on Molecular, Antigen and Serology Tests Shipments

By LabMedica International staff writers
Posted on 23 Jul 2020
A new US national testing registry has been launched to aid in the fight against COVID-19 and has released the first data set that shows more than 65 million tests have been shipped nationwide since the beginning of the pandemic.

This comprehensive, national COVID-19 diagnostic supply registry has been created by the Advanced Medical Technology Association (AdvaMed Washington, D.C., USA) to help state and federal governments in their pandemic responses. The national registry is being launched in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. AdvaMed has been working closely with the White House, HHS, FDA, FEMA and other key government agencies to ensure the continued supply of diagnostics tests, as well as other vital medical equipment such as PPE and ventilators, in the fight against the COVID-19 pandemic.


AdvaMed’s registry will compile information from diagnostic companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. It will provide weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the US. AdvaMed’s registry will help streamline communications and data sharing between diagnostic companies and federal and state governments as well as standardize test supply reporting. It will also facilitate collaboration with laboratories and other public health stakeholders to optimize access to all platforms of COVID-19 testing so that any potential shortages are identified and addressed quickly. The registry’s first publicly released dataset shows that since the beginning of the pandemic, more than 65 million tests have been manufactured and shipped nationwide, with test shipments now topping 800,000 daily.

“It is absolutely vital to our nation’s health and economic recovery that we have sufficient supplies to test everyone who needs it, and, just as important, to know where these supplies are so we can get them where they are most needed,” said Scott Whitaker, president and CEO of AdvaMed. “This national registry will be a crucial tool for federal and state authorities as they work to protect both patients and health care providers and move to reopen the U.S. economy.”

“We hope this registry serves as a key tool in our fight against COVID-19. We stand ready to partner with all providers, laboratories and other key stakeholders in the testing ecosystem to collaborate with the federal and state governments to coordinate efforts to support patient care and public health. Further, we stand ready to work with our partners in the federal government on any policies that would allow this registry to better serve patients and providers in need,” Whitaker concluded.

Related Links:
Advanced Medical Technology Association (AdvaMed)

Latest COVID-19 News